Other languages Gossamer Bio, Inc.

Equities

GOSS

US38341P1021

Real-time Estimate Cboe BZX Other stock markets 07:59:10 14/05/2024 pm IST			5-day change	1st Jan Change
0.712 ^USD	-1.11%		-1.57%	-21.10%

07/05	Gossamer Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
06/05	Chiesi Farmaceutici S.P.A Gossamer Bio, Inc Announces Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Gossamer Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Chiesi Farmaceutici S.P.A Gossamer Bio, Inc Announces Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications	06/05
Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment	06/05
Gossamer Bio Announces Publication of Torrey Phase 2 Results in the Lancet Respiratory Medicine	03/05
Gossamer Bio Announces Board of Directors Appointments	12/03
Gossamer Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05/03
Gossamer Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	05/03
Gossamer Bio Inc. Appoints Bob Smith as Chief Commercial Officer	05/12
Gossamer Bio, Inc. Appoints John Quisel to Its Board of Directors	29/11
Gossamer Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Gossamer Bio, Inc. Announces Resignation of Kristina Burow from the Board of Directors	08/23/08
Gossamer Bio, Inc. to Present Results of TORREY FRI Sub- Study At the European Respiratory Society International Congress 2023	07/23/07
Gossamer Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/23/09
Sector Update: Health Care Stocks Gaining Late Thursday	21/23/21
Sector Update: Health Care Stocks Gaining Thursday Afternoon	20/23/20
Gossamer Bio to Sell 129.9 Million Shares, Accompanying Warrants in Private Placement to Raise $212 Million; Shares Fall	20/23/20
Gossamer Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/23/10
Gossamer Bio Ends Development of Lymphoma Drug Candidate GB5121 After FDA Partial Hold	04/23/04
Gossamer Bio Inc. Announces FDA has Placed a Partial Clinical Hold on All Trials of GB5121 in Response to Serious Adverse Events	04/23/04
Gossamer Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	17/23/17

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Gossamer Bio, Inc.

Equities

GOSS

US38341P1021

Other languages

Filters